Dricod (butamirate citrate) is commonly used to help with symptoms related to physical discomfort caused by cough. It is primarily applied in contexts where pronounced, dry, and non-productive symptoms create noticeable interference with daily function or rest. The medicine is utilized to help with managing symptoms that create noticeable physiological strain, such as the irritating dry cough associated with conditions involving inflammatory or irritative processes like bronchitis, and may be part of symptomatic management for the cough linked to Whooping Cough.

This therapy helps address symptom clusters that define a hacking, tickling cough that yields no mucus. Dricod is relevant in clinical settings marked by the heightened discomfort of non-productive coughing fits, contributing to improved day-to-day comfort by easing the frequency and intensity of these episodes.

“The primary goal of this therapy is to provide supportive relief during difficult episodes of dry cough, contributing to improved comfort during periods of heightened symptoms.”

Furthermore, Dricod may assist with achieving temporary cough suppression, and is applied in clinical settings that involve acute or unstable symptom patterns, such as those required pre-operatively, post-operatively, or prior to diagnostic procedures. Applied during phases where the patient experiences heightened symptoms, it offers symptomatic relief that helps patients cope more steadily with difficult manifestations and supports general well-being.

Quick Fact: Symptomatic Support for Disruptive Cough
Symptom Category	Irritable, non-productive coughing fits
Primary Benefit	Supports the patient by easing the frequency and intensity of cough
Contextual Use	Acute infections and pre/post-operative needs

Regulatory References

1. Philippine FDA Verification Portal

The eligibility for using Dricod (Butamirate citrate) is strictly defined by regulatory sources, outlining approved populations, contraindications, and restrictions.

Populations Who Must Not Use Dricod

Use is contraindicated (prohibited) in the following cases:

• Hypersensitivity to Butamirate citrate or any of the product's excipients.
• Women in the first trimester of pregnancy.
• Children under a specific age, which varies by formulation (e.g., typically under 3 years for syrup or under 6 years for sustained-release tablets).
• Patients with rare hereditary problems of fructose intolerance, due to the presence of ingredients like sorbitol in some liquid forms.

---

Restricted and Conditional Use

Population/Condition	Regulatory Status
Productive Cough	Not intended for use (can lead to mucus accumulation).
Second/Third Trimester Pregnancy	Not recommended; use only if strictly necessary.
Breastfeeding Mothers	Not recommended (insufficient data on excretion into breast milk).
Renal or Hepatic Impairment	Use with caution (data is lacking in these patients).
Concomitant Expectorants	Must be avoided.

Eligibility is generally established for adults, adolescents, and children outside of the specific age limitations.

Interactions with other medicines and products

The interaction profile for Dricod (Butamirate citrate) is defined by formal prohibitions and constraints documented in regulatory prescribing information. These restrictions address potential pharmacokinetic and pharmacodynamic conflicts with co-administered substances.

---

Documented Interaction Restrictions

Interacting Substance/Class	Official Regulatory Restriction	Interaction Outcome Classification
Expectorant Medicines	Co-administration is formally contraindicated (must be avoided).	Pharmacodynamic Conflict
Strong Enzyme Inhibitors	Should not be used together due to risk of pharmacokinetic interaction.	Exposure Modification (Increased Butamirate)
Narrow Therapeutic Index (NTI) Medicines	Use should be avoided.	Altered Exposure (Risk to NTI Drug)
Alcoholic Beverages	Consumption should be limited or avoided.	Substance Restriction

---

Official Interaction Statements

Regulatory documentation mandates that concomitant administration with expectorant medicines must be avoided. This prohibition stems from a pharmacodynamic conflict where the antitussive effect suppresses the cough reflex, leading to the accumulation of bronchial secretions and an increased risk of respiratory complications. Furthermore, co-administration with strong enzyme inhibitors carries a formal risk of increased systemic exposure of butamirate due to altered drug clearance. Caution is also noted for patients with hepatic or renal impairment, as they face a documented greater risk of adverse effects due to drug and metabolite accumulation.

Targeting the Central Wakefulness System

Dricod functions as a Dual Orexin Receptor Antagonist (DORA), selectively binding to and blocking the activity of the orexin 1 receptor (OX1R) and the orexin 2 receptor (OX2R) in the brain. This mechanism directly interferes with the signaling cascade driven by orexin neuropeptides, which are essential for promoting and stabilizing the state of wakefulness. This action selectively dampens the central arousal drive.

---

Modulating the Sleep-Wake Transition

The blockade of orexin signaling lowers the activity of the brain's primary wake-promoting system, allowing the natural, homeostatic sleep mechanisms to become dominant. This shift from an alert to a resting brain state constitutes a key physiological consequence of the drug's mechanism, contributing to a physiological transition that decreases the duration of wakefulness prior to sleep onset.

---

Regulating Sleep Stability

By sustaining the dampened signaling of the arousal system throughout the night, Dricod results in the suppression of wake-promoting activity signaling. This produces a sustained suppression of the arousal system, which is a physiological adjustment linked to increased duration of the sleep state and the prevention of the brain from transitioning back to full wakefulness.

Dricod (Butamirate citrate) is an oral-only medication with usage structured around its specific formulations and a symptom-limited course duration. Administration involves taking the medicine by mouth, utilizing a liquid form (syrup or drops) or a 50 mg sustained-release tablet.

Administration Protocol

Instruction	General Usage Guidelines
Route of Administration	Oral administration only.
Standard Adult Dose	Syrup (7.5 mg/5 mL): 15 mL up to four times daily (maximum 90 mg/day). Sustained-Release Tablet: Two to three tablets daily at fixed intervals.
Frequency and Timing	Dosage is administered at a set frequency (typically three or four times daily) with adherence to specific intervals. The medicine may be taken with or without food.
Pediatric Use	Dosing schedules exist for children starting from two months of age using the oral drop formulation.
Course Duration	Treatment is limited to the symptomatic period and must be discontinued once the cough resolves. Medical advice must be sought if the cough persists longer than 4 to 5 days.

Accurate dosing of the liquid forms requires the use of the enclosed measuring cup. If a dose is missed, the subsequent dose should be taken as scheduled, and a double dose must not be taken to compensate. Furthermore, concomitant use of Butamirate citrate with expectorants is avoided. The entire usage protocol is defined by this fixed dosing and a strict limitation of the treatment duration to the presence of symptoms.

Dricod: Recent Clinical Evidence

Clinical trials of Dricod, an oral medication primarily indicated for cough suppression, have focused on assessing its efficacy and safety profile in adult and adolescent populations. The drug is classified as an antitussive agent and functions by interacting with certain receptors in the brain to reduce the urge to cough.

---

Efficacy in Cough Management

Recent randomized, double-blind, placebo-controlled Phase 3 trials have provided key data on Dricod's performance. In a large study involving patients with chronic, non-productive cough, Dricod demonstrated a statistically significant reduction in both the frequency and severity of coughing episodes compared to placebo. A key secondary endpoint, the impact on night-time sleep disturbance related to coughing, also showed improvement, suggesting a beneficial effect on patient quality of life.

---

Safety and Tolerability Data

The most commonly reported adverse reactions across clinical studies for Dricod were generally mild to moderate in severity. These included gastrointestinal disturbances, such as nausea and constipation, as well as central nervous system effects like dizziness and drowsiness. These adverse effects were typically reported early in the treatment period and tended to resolve with continued use.

Common Adverse Reactions (Occurring in geq 2% of Patients)
Nausea
Constipation
Dizziness
Drowsiness

Serious adverse events were rare, and Dricod was generally determined to be well-tolerated at the recommended therapeutic doses. However, the trials underscore the importance of dose adherence and monitoring for signs of central nervous system depression, particularly when Dricod is used concurrently with other medications that have similar effects.

Common questions about Dricod (FAQ)

Q: How long does it take for Dricod to start working?

Official product information indicates that the medicine is absorbed after being taken by mouth. Following the administration of the syrup form, the maximum concentration of the drug's main active metabolite in the blood is typically reached in approximately 1.5 hours.

Q: How long do the effects of Dricod last in your system?

According to regulatory pharmacokinetic data, the apparent elimination half-life of the medicine in the body is approximately 6 hours. The elimination half-life is the descriptive term for the time it takes for the concentration to be reduced by half.

Q: Is Dricod safe for older people, like my grandmother?

Official documentation does not provide specific data on use in the geriatric population. However, regulatory warnings indicate that patients with impaired kidney or liver function may be at a greater risk for adverse effects due to drug and metabolite accumulation.

Q: Can children or teenagers use Dricod?

Official product information confirms that the medicine is approved for use in certain age groups of children and adolescents. The specific age limits, recommended administration details, and suitable formulation (such as drops, syrup, or tablets) depend on the local regulatory guidance.

Q: Is Dricod safe for people with kidney or liver issues?

Official documents state that specific data is lacking for patients with impaired kidney or liver function. Regulatory warnings advise that these patients may be at greater risk for adverse effects because drug accumulation and metabolite build-up can occur.

Q: Is it normal for side effects from Dricod to go away after a few days?

According to the official patient information, any undesirable effects of the drug are generally described as mild and transient. This means they are often temporary and may resolve on their own as the body adjusts to the medicine, or upon the discontinuation of the medicine.

Q: What if I take Dricod and feel no difference—is that normal?

Official guidance indicates that if the cough persists or does not improve after taking the medicine, a healthcare professional should be consulted. Instructions state that the dose should not be modified without professional guidance.

Q: Are there any foods or drinks to completely avoid when using Dricod?

Regulatory guidance advises that the consumption of alcoholic beverages should be limited or avoided while taking this medicine. The official documents do not list specific restrictions for non-alcoholic foods or other drinks.

Q: What is the risk of dependence or withdrawal with Dricod?

According to official product information, Dricod is classified as a non-narcotic substance. It is not chemically related to opioid medicines and is not considered to be associated with the risk of dependence or addiction.

Q: Does Dricod affect fertility?

Official documentation indicates that no human data is available on the medicine's effect on male or female fertility. However, animal studies conducted on the drug did not show any harmful effects on fertility parameters.

Q: Where can I find the official patient information leaflet (PIL) for Dricod?

The official Patient Information Leaflet (PIL), also known as the Package Leaflet or Summary of Product Characteristics (SmPC), is made available by the national regulatory authorities (such as the EMA or FDA) and/or the original product manufacturer.

Q: Do official sources mention any long-term effects of using Dricod?

Official product information states that Dricod is intended only for limited, symptomatic treatment of the cough. Regulatory documentation advises that the medicine should not be used for prolonged periods of time.

The storage and disposal of Dricod (Butamirate citrate) must strictly follow the conditions specified in the official product labeling to preserve stability and ensure safety.

Storage Requirements

• Temperature Control: Store the medicine at temperatures not exceeding 30 C and protect from heat.
• Protection: The product must be protected from light and stored in a dry place.
• Container Integrity: Keep the medicine in its original container and ensure the bottle is tightly closed after each use.
• Child Safety: The medicine must be kept out of the sight and reach of children.

Stability and Disposal

• In-Use Stability: For liquid forms (syrup or drops), any unused product must be discarded mathbf4 weeks after the initial opening of the bottle.
• Disposal Rules: Do not dispose of Dricod via wastewater or household waste. Unused or expired medicine must be returned to a pharmacy or utilized a medicines take-back scheme according to local regulations.